- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01588002
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
November 1, 2016 updated by: Hoffmann-La Roche
A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers
This phase 1, randomized, open-label, multiple-dose, 2-sequence, 2-period crossover study will evaluate potential drug-drug interaction between efavirenz and danoprevir with low-dose ritonavir in healthy volunteers.
In Period 1. subjects will be randomized to receive multiple oral doses of either danoprevir with ritonavir or efavirenz for 14 days.
In Period 2, all subjects will receive multiple oral doses of the combination danoprevir with ritonavir and efavirenz for 14 days.
Anticipated time on study treatment is 28 days.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female non-smoking subjects, 18 to 55 years of age
- Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
- Medical history without major, recent or ongoing pathology
- Weight >/= 50.0 kg
- Body mass index (BMI) 18.0 - 32.0 kg/m2
Exclusion Criteria:
- Pregnant or lactating women or males with female partners who are pregnant or lactating
- History of any clinically significant medical condition which may impact the safety of the participant
- Positive results for drugs of abuse at screening or prior to admission to the clinical site during any study period
- Positive for hepatitis B, hepatitis C or HIV infection
- Current smokers or subjects who have discontinued smoking less than 6 months prior to first dose of study medication
- Use of hormonal contraceptives (e.g. birth control pill, patches, or injectable, implantable devices) within 30 days before the first dose of study medication
- Use of investigational drug or device within 30 days of the first dose of study medication (6 months for biologic therapies) or 5 half-lives of the investigational drug, whichever is longer
- History of drug-related allergic reaction
- History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average; alcohol consumption will be prohibited 72 hours prior to entry in the clinical site center and throughout the entire study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A danoprevir+ritonavir
|
multiple oral doses
multiple oral doses
|
Active Comparator: B efavirenz
|
multiple oral doses
|
Experimental: C combination
|
multiple oral doses
multiple oral doses
multiple oral doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Cmax
Time Frame: Pre-dose and up to 24 hours post-dose on Days 14 and 28
|
Pre-dose and up to 24 hours post-dose on Days 14 and 28
|
Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Area under the concentration-time curve (AUC)
Time Frame: Pre-dose and up to 24 hours post-dose on Days 14 and 28
|
Pre-dose and up to 24 hours post-dose on Days 14 and 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Incidence of adverse events
Time Frame: approximately 2 months
|
approximately 2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
April 19, 2012
First Submitted That Met QC Criteria
April 26, 2012
First Posted (Estimate)
April 30, 2012
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Ritonavir
- Efavirenz
Other Study ID Numbers
- NP28103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
National Heart, Lung, and Blood Institute (NHLBI)TerminatedHealthy | Healthy Volunteer | HVUnited States
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
Clinical Trials on danoprevir
-
Hoffmann-La RocheCompletedHepatitis C, ChronicNew Zealand, Australia
-
University of ExtremaduraActive, not recruitingFibromyalgia | Chronic Fatigue Syndrome | Comorbidities and Coexisting ConditionsSpain
-
Hoffmann-La RocheCompletedHepatitis C, ChronicUnited States, Canada, Australia, France, Germany, Austria, Italy
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
Damascus UniversityCompletedOrthodontic Appliance Complication | Pain and DiscomfortSyrian Arab Republic
-
Hoffmann-La RocheCompletedHealthy VolunteerFrance
-
Huoshenshan HospitalAscletis Pharmaceuticals Co., Ltd.Completed
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedHealthy VolunteerSlovakia, United States, Czech Republic
-
Hoffmann-La RocheCompleted